Mr. George Tziras reports

HELUS PHARMA STRENGTHENS SCIENTIFIC ADVISORY BOARD WITH ADDITION OF DR. ROBERT LANGER AND DR. STEPHEN BRANNAN

Cybin Inc. (doing business as Helus Pharma) has added Dr. Robert Langer and Dr. Stephen Brannan to its scientific advisory board.

Helus Pharma's scientific advisory board supports the company's commitment to advancing its pipeline through disciplined drug development and scientific rigour. The addition of Dr. Langer and Dr. Brannan reflects the company's continued focus on grounding innovation in robust clinical evidence as it advances programs designed to address significant unmet needs in mental health. The scientific advisory board is chaired by Dr. Freda Lewis-Hall, former executive vice president and chief medical officer at Pfizer, who provides leadership across clinical development strategy, regulatory engagement and translational execution.

"Strengthening our scientific advisory board with these two leaders is a major milestone as we advance our pipeline," said Eric So, interim chief executive officer of Helus Pharma. "Dr. Langer is globally recognized for translating groundbreaking science into therapies that reach patients, and Dr. Brannan brings decades of leadership in advancing central nervous system (CNS) programs through clinical development. Their complementary expertise strengthens our scientific foundation as we progress our novel serotonergic agonists, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder."

"I've always believed that the work I do should ultimately translate into real impact for patients," said Dr. Langer. "Helus Pharma is advancing innovative approaches to mental health through disciplined clinical development and thoughtful application of new science. The company's commitment to transforming novel discoveries into meaningful therapies aligns strongly with how I approach research, innovation, and helping people."

"There remains significant unmet need in serious psychiatric disorders, and advancing new therapies requires rigorous clinical development and careful execution," said Dr. Brannan. "Helus Pharma's commitment to disciplined science and scalable treatment models aligns closely with my experience in bringing CNS therapies through development, and I look forward to supporting the advancement of its pipeline."

Dr. Langer is a world-renowned leader in biotechnology and drug delivery. He leads Langer Lab, the largest biomedical engineering laboratory in the world. Dr. Langer has authored more than 1,600 scientific papers and holds over 1,500 issued and pending patents worldwide. He has helped found more than 40 biotechnology companies, including Moderna, Inc., and has received more than 220 major awards for his work, including the Queen Elizabeth Prize for Engineering, the United States National Medal of Technology and Innovation, and the United States National Medal of Science.

Dr. Brannan is a physician-scientist and clinical development leader with extensive expertise in CNS therapeutics. He is the former chief medical officer at Karuna Pharmaceuticals, where he oversaw clinical development of innovative therapies targeting serious psychiatric disorders. Previously, Dr. Brannan served as vice-president and therapeutic area lead for neuroscience clinical development at Takeda Pharmaceuticals, where he led development programs focused on mood and anxiety disorders. Across his career, Dr. Brannan has played a pivotal role in advancing novel CNS therapies through clinical development, regulatory engagement and late-stage execution.

About Cybin Inc. (Helus Pharma)

Helus Pharma, the commercial operating name of Cybin, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs -- novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the United States Food and Drug Administration and HLP004, also a proprietary NSA in phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland.

We seek Safe Harbor.